Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study

Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study

Yu-Hung Fang,1 Yao-Hsu Yang,2–5 Meng-Jer Hsieh,6,7 Ming-Szu Hung,8,9 Yu-Ching Lin1,8 1Division of Thoracic Oncology, Department of Pulmonary and Critical Care Medicine, Chang Gung Memorial Hospital, Chiayi Branch, Puzi City, Chiayi County, Taiwan, R.O.C; 2Department of Traditional Chinese...

Full description

Bibliographic Details
Main Authors:	Fang YH, Yang YH, Hsieh MJ, Hung MS, Lin YC
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-09-01
Series:	Cancer Management and Research
Subjects:	proton pump inhibitor epidermal growth factor receptor non-small cell lung cancer gefitinib tyrosine kinase inhibitor National Health Insurance Research Database.
Online Access:	https://www.dovepress.com/concurrent-proton-pump-inhibitors-increase-risk-of-death-for-lung-canc-peer-reviewed-article-CMAR

Similar Items

Mechanism of TRIM24 to Regulate Resistance of Gefitinib in NSCLC cells
by: Haiying LI, et al.
Published: (2016-01-01)

Combination Use of First-Line Afatinib and Proton-Pump Inhibitors Reduces Overall Survival Among Patients with EGFFR Mutant Lung Cancer
by: Ho MC, et al.
Published: (2022-12-01)

Critical Appraisal of Gefitinib in the Treatment of Non-Small Cell Lung Cancer
by: Yung-Hung Luo, et al.
Published: (2015-09-01)

Not COVID-19, Don’t Overlook Pneumocystis in Patients on Gefitinib!
by: Jérémy Barben, et al.
Published: (2021-02-01)

Proton pump inhibitors overuse - consequences among patients
by: Patrycja Kmiotek, et al.
Published: (2019-08-01)

Proton pump inhibitors overuse - consequences among patients
by: Patrycja Kmiotek, et al.
Published: (2019-08-01)

Clinical impact of tetracyclines and/or proton pump inhibitors on the efficacy of epidermal growth factor receptor inhibitors in non-small cell lung cancer: a retrospective cohort study
by: Hui-Hsia Hsieh, et al.
Published: (2023-02-01)

Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper
by: Jean-Luc Raoul, et al.
Published: (2022-02-01)

Proton pump inhibitors overuse: only inappropriate prescriptions or further iatrogenic damage?
by: Mario Visconti
Published: (2015-09-01)

Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists
by: Angel A. T. Uchiyama, et al.
Published: (2021-02-01)

Use of Proton Pump Inhibitors in Hungary: Mixed-Method Study to Reveal Scale and Characteristics
by: Mária Matuz, et al.
Published: (2020-09-01)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
by: Shih-Chieh Chang, et al.
Published: (2011-06-01)

Aspartames Alter Pharmacokinetics Parameters of Erlotinib and Gefitinib and Elevate Liver Enzymes in Wistar Rats
by: Hajer AlRasheed, et al.
Published: (2022-11-01)

A dual role of proton pump inhibition on cancer: a critical review
by: Edizer Deniz Tuna, et al.
Published: (2023-02-01)

Effect of Concomitant Proton Pump Inhibitors with Pazopanib on Cancer Patients: A Retrospective Analysis
by: Camille Moreau-Bachelard, et al.
Published: (2022-09-01)

Proton pump inhibitors- Adversaries in our fight against antibiotic resistance?
by: Sumayya Umar, et al.
Published: (2023-10-01)

Proton Pump Inhibitors and Gastric Cancer
by: Seungkyung Kang, et al.
Published: (2021-09-01)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
by: Zhonghan Zhang, et al.
Published: (2019-11-01)

Incidence of hypomagnesemia on proton pump inhibitors at the Huntington Veterans Affairs Medical Center – IHOP
by: Ebrahim Sabbagh, et al.
Published: (2016-07-01)

Flavoured water consumption alters pharmacokinetic parameters and increases exposure of erlotinib and gefitinib in a preclinical study using Wistar rats
by: Aliyah Almomen, et al.
Published: (2020-09-01)

Proton Pump Inhibitors: Are we prescribing them right?
by: Eduardo Esteban-Zubero
Published: (2021-10-01)

Correlation of Proton Pump Inhibitors with Pulmonary Tuberculosis: A Case-Control Study in Taiwan
by: Kao-Chi Cheng, et al.
Published: (2017-07-01)

Proton pump inhibitors and dementia: what association?
by: Catarina Caetano, et al.
Published: (2023-05-01)

Proton pump inhibitors usage and the risk of cancer
by: Hubert Wróblewski, et al.
Published: (2021-08-01)

Deleterious association between proton pump inhibitor and protein kinase inhibitor exposure and survival for patients with lung cancer: A nationwide cohort study
by: Constance Bordet, et al.
Published: (2024-01-01)

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma
by: Krisztian Homicsko, et al.
Published: (2022-05-01)

Proton Pump Inhibitors: Are They a Real Threat to the Patient?
by: Sofia Xavier, et al.
Published: (2018-02-01)

Mucocutaneous side effects of gefitinib
by: Ruhaila Thekkath, et al.
Published: (2021-01-01)

Influence of proton pump inhibitor therapy on intestinal inflammation assessed by fecal calprotectin in pediatric patients
by: Su Yeong Kim, et al.
Published: (2019-10-01)

Safety and Potential Risks of Prolonged Use of Proton Pump Inhibitors
by: S.M. Tkach
Published: (2014-02-01)

Effects of proton pump inhibitor use on the esophageal microbial community
by: Sadia Tasnim, et al.
Published: (2020-09-01)

Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death
by: Ping Chen, et al.
Published: (2019-06-01)

Concomitant Use of Antiplatelet Agents and Proton-Pump Inhibitors Increases the Risk of Adverse Cardiovascular Events: A Nationwide Population-Based Cohort Study Using Balanced Operational Definitions
by: Hee Gyu Yang, et al.
Published: (2023-06-01)

Proton Pump Inhibitors Increase the Risk of Autoimmune Diseases: A Nationwide Cohort Study
by: Sheng-Hong Lin, et al.
Published: (2021-09-01)

The Association between Baseline Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Chemotherapy: A Systematic Review with Network Meta-Analysis
by: Yu Chang, et al.
Published: (2022-12-01)

Reasons for initiation of proton pump inhibitor therapy for hospitalised patients and its impact on outpatient prescription in primary care
by: Elena Villamañán, et al.
Published: (2015-11-01)

Effect of Proton Pump Inhibitors in Bronchiectatic Patients with Gastroesophageal Reflux Disease
by: Byungkyu Ahn, et al.
Published: (2016-07-01)

Proton pump inhibitor use is associated with hip fracture development: a nationwide population-based cohort study
by: Yang Won Min, et al.
Published: (2020-09-01)

Proton pump inhibitors induce hemolytic anemia
by: Asayil Nasser Al-Nasser, et al.
Published: (2019-01-01)

Changes in serum magnesium concentration after use of a proton pump inhibitor in patients undergoing percutaneous coronary intervention
by: Sang-Ho Park, et al.
Published: (2015-06-01)